London-based biotech Purespring Therapeutics plans to bring their kidney-tweaking gene therapy to the clinic with the help of ...

Purespring Therapeutics has raised $105m in a Series B funding round which will help progress its lead candidate PS-002 to ...

Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases ...

Purespring Therapeutics Ltd. has raised £80 million (US$104.6 million) in a series B, putting it on course to be the first to ...

A University of Bristol spinout company focused on transforming the way kidney diseases are treated has announced an £80m ...

Purespring raises £80 million in a Series B financing, with Syncona committing £19.9 million[1] as part of a leading syndicate of life science investorsProceeds will be used to advance Purespring’s ...

Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases ...

Life science investor Syncona said its portfolio company Purespring Therapeutics, which focuses on gene therapies for kidney diseases, had raised £80m in an oversubscribed financing.

Our round-up of recent biotech financings features a strong first round for City Therapeutics, a new RNAi venture led by ...

Syncona is a London-based life science investor that owns a diversified portfolio of companies spanning across clinical stages. Purespring Therapeutics is an investee company of Syncona. It is focused ...

Purespring Therapeutics, a UK-based gene therapy company focused on kidney disease, has raised £80 million ($105 million) in ...

The UK cell therapy biotech will now advance its first candidate cell therapy to clinical trials for treatment of liver ...